Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quban Powder is a Traditional Chinese Medicine (TCM) formulation developed by Guang'anmen Hospital, China Academy of Chinese Medical Sciences, for the treatment of melasma. The formulation is based on the TCM therapeutic principle of "promoting blood circulation and removing stasis" (Huoxue Huayu), which aims to address the underlying pathological factors of blood stasis believed to contribute to facial hyperpigmentation. Clinical research, including trial ChiCTR2300076869, has utilized reflectance confocal microscopy (RCM) to objectively evaluate the efficacy of Quban Powder in reducing pigment deposition and improving skin structure in patients with melasma. As a hospital-developed preparation, it typically consists of a combination of botanical ingredients known for their ability to improve microcirculation and potentially inhibit melanogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Quban Powder (Guang'anmen Hospital).